Compare TG Therapeutics Inc (TGTX) vs Wynn Resorts, Limited (WYNN) Price & Performance

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.

Wynn Resorts (WYNN) trades at $103.51, up 0.99% today, showing steady recovery from pandemic lows. The stock maintains bullish technical signals with strong institutional support, though faces headwinds from high debt levels and margin pressure. Recent Q2 2026 earnings beat expectations with $1.24 EPS versus $0.99 estimate, driven by Macau strength, while Las Vegas operations show slower growth. Analyst consensus remains strongly bullish with 64% buy ratings and $133 price target, representing 28% upside potential.

Investment outlook balances growth potential against significant risks. The company's Macau recovery and UAE expansion provide growth catalysts, but high leverage ($10.5B debt) and rising capex for Wynn Al Marjan project create cash flow pressure. Current valuation at 25x P/E appears reasonable given recovery trajectory, but investors should monitor margin trends and capital expenditure discipline closely given the negative shareholder equity position.